Clinical Outcome Measures in Friedreich's Ataxia

Purpose	The purpose of this study is to identify ways to follow the progression of FRDA and to measure clinical and biochemical changes over a short period of time. We hope that these studies will identify outcome measures to be used in future clinical trials. In addition, we are sampling blood to gather genetic material, or DNA from persons with Friedreich's Ataxia to learn more about how genes affect the development of Friedreich's Ataxia. These genetic studies may help us learn more about the clinical variability of FRDA, for example why some people have severe scoliosis, hearing loss, etc....and others do not.
Details	Study Number 22868	Accepts Adults? Yes	Accepts Children? Yes	Fully Enrolled? No
Contacts	Principal Investigator Bernard Ravina, MD	Contact Cheryl Deeley, 585-341-7500

Please call the phone number listed above and the clinical trial coordinator will contact you.